Global Health working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

26.75×	26.75×	27.80×	30.58×	33.20×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
29.09×	29.09×	25.07×	22.82×	25.36×
80.04×	80.04×	79.17×	91.68×	96.03×
−24.20×	−24.20×	−26.30×	−38.28×	−37.47×
4.47×	4.21×	4.04×	3.68×	2.68×
0.83×	0.83×	0.81×	0.78×	0.74×
1.29×	1.29×	1.30×	1.28×	1.98×
0.78×	0.78×	0.71×	0.77×	1.05×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDANTA₹1,299.70

Global Health Ltd.

· Pharma & Health

₹ CrorePeersMAXHEALTH APOLLOHOSP FORTIS GLAXO ANTHEM AJANTPHARM IPCALAB ABBOTINDIAMcap ₹34,922 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	33.20	30.58	27.80	26.75	26.75
Receivable Days (DSO)	25.36	22.82	25.07	29.09	29.09
Payable Days (DPO)	96.03	91.68	79.17	80.04	80.04
Cash Conversion Cycle (days)	-37.47	-38.28	-26.30	-24.20	-24.20
Working Capital Turnover	2.68	3.68	4.04	4.21	4.47
Asset Turnover	0.74	0.78	0.81	0.83	0.83
Cash Conversion (CFO/Net Income)	1.98	1.28	1.30	1.29	1.29
CFO/EBITDA	1.05	0.77	0.71	0.78	0.78

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.